Peptides Explained

Eli Lilly is taking legal action against businesses selling products labeled retatrutide. What do the lawsuits actually establish—and what don't they? John Garrett separates pending legal allegations from court findings, reviews the human trial evidence for the investigational triple agonist, and explains why molecular identity, purity, and pharmaceutical equivalence are not interchangeable. We also examine FDA restrictions, consumer safety, and the implications for clinics, vendors, and independent educators. Educational only; not medical or legal advice. Retatrutide is not FDA-approved. Sources: NEJM DOI 10.1056/NEJMoa2301972; FDA unapproved GLP-1 drug concerns; ClinicalTrials.gov NCT05929066 and NCT05882045.

Everyone keeps calling belly fat "visceral fat." That is not how anatomy works. In this crossover episode, John breaks down the difference between visceral and subcutaneous fat, why visceral adipose tissue matters metabolically, how it is actually measured, what waist circumference can and cannot tell you, and what the evidence says about GLP-1 therapies and tesamorelin.

FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.

Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them? John breaks down glutathione biology, the GSH/GSSG cycle, oral human data, NAC, skin-related research and the gap between changing a biomarker and changing a meaningful health outcome. The episode also covers the 2026 FDA warning and recalls involving compounded injectable glutathione and elevated endotoxin levels. The key question: where does established biology end and wellness marketing begin? Educational only. Not medical advice.

Download The Peptide App at ThePeptide.App/Explained For more information on research peptides check out PeptidesExplained.info/OfflinePeptides A peptide…in a pill? Icotyde, or icotrokinra, is an FDA-approved oral peptide designed to block the IL-23 receptor in moderate-to-severe plaque psoriasis. In Phase 3 trials, it produced substantial skin clearance and outperformed an established oral comparator on several key endpoints. But the biggest story may be the delivery platform itself. Peptides usually struggle to survive the digestive tract and reach circulation. Icotyde shows what can happen when medicinal chemistry, structural engineering and extreme receptor potency come together. This episode breaks down what worked, what the safety data show, and what this does—and does not—mean for the future of oral peptides. Educational only. Not medical advice.

Download The Peptide App @ ThePeptide.App/Explained For more info on research peptides visit PeptidesExplained.info/OfflinePeptides John Garrett shares his N=1 experience with the so-called "Trinity Stack"—established TRT, retatrutide, and tesamorelin—combined with resistance training, Zone 2 cardio, high protein intake, creatine, sauna, and cold plunging. The transformation was dramatic. But what likely came from appetite control? What helped preserve muscle? What might the GH/IGF-1 axis have added? And how much credit belongs to the boring fundamentals? This is a candid personal testimony and accessible science breakdown—not a deep dive, a dosing guide, or a warning lecture. John also explains what happened during an eight-week break and why he recently restarted with a goal of reaching 10% body fat. Educational only. Retatrutide remains investigational and is not FDA-approved.

Visit peptidesexplained.info for more info and resources For more info on research peptides check out PeptidesExplained.info/OfflinePeptides or email John at [email protected] What exactly is GLP-1 microdosing? Depending on who you ask, it can mean remaining on the starter dose, taking a fraction of that dose, spacing injections farther apart, stepping down after weight loss, or using a tiny amount for food noise and longevity. Those are not the same strategy. John Garrett breaks down the new low-dose semaglutide and tirzepatide data, FDA-approved dose structures, weight-regain research, maintenance questions, side effects, and the major gap between individualized clinical titration and social-media "microdosing" protocols. Educational content only. Not medical advice.

Check out The Peptide App here: thepeptide.app/explained What is Pinealon, and does this three-amino-acid peptide really protect the aging brain? Pinealon—also called EDR or Glu-Asp-Arg—is a synthetic tripeptide associated with the Khavinson bioregulator research program. It is discussed for memory, neuroprotection, oxidative stress, brain aging, and even Alzheimer's disease, but the evidence is much more complicated than the marketing language suggests. John Garrett, examines Pinealon's proposed mechanism, cell and animal research, a newer induced-neuron study, and the PubMed-indexed human reports that are often overlooked. The episode also explains why Pinealon is different from Epitalon, where the human evidence is weak, what remains unknown about brain exposure and long-term safety, and why a plausible mechanism is not the same thing as an established cognitive therapy. Educational content only. Not medical advice.

Does a weight-loss plateau mean your GLP-1 receptors have become desensitized? John separates cellular receptor biology from whole-body weight regulation and compares semaglutide, tirzepatide, and investigational retatrutide. We examine appetite suppression, food noise, gastric-emptying tachyphylaxis, metabolic adaptation, switching therapies, and what the clinical evidence can—and cannot—tell us. A plateau is real. "Receptor burnout" is a much bigger claim. Educational only; not medical advice.

ARA-290, also called cibinetide, is an investigational 11-amino-acid peptide designed from erythropoietin biology to activate tissue-protective signaling without stimulating red-blood-cell production. In this episode, John Garrett, RN, breaks down the innate repair receptor, why ARA-290 has been studied in small-fiber neuropathy, what randomized human trials in sarcoidosis and type 2 diabetes actually found, and why objective nerve-fiber signals are interesting—but not the same thing as an approved therapy. You'll learn: • What ARA-290/cibinetide is • How it differs from full-length erythropoietin • What the innate repair receptor is • Why researchers studied corneal nerve fibers • What the 22-patient pilot trial showed • What the 64-patient phase 2b trial showed • Why pain and nerve-fiber endpoints did not tell exactly the same story • What is known—and not known—about safety • Why online ARA-290 products should not be assumed equivalent to trial material Explore the Peptides Explained app: app.peptidesexplained.info Learn more through Peptide Solutions: peptide-solutions.info Educational content only. ARA-290 is investigational and is not an FDA-approved treatment for neuropathy or any other clinical indication.

FOXO4-DRI has been called a "zombie-cell killer," a senolytic peptide, and even a possible anti-aging breakthrough. The mechanism is fascinating—but the claims have moved much faster than the human evidence. In this episode, John explains what senescent cells are, why they are not automatically harmful, and how FOXO4 and p53 help regulate cell survival and cell death. He then breaks down the D-retro-inverso design of FOXO4-DRI, the proposed mechanism, and what the original 2017 research actually found in cultured human cells and mice. The episode also examines what has happened since that first study, why removing senescent cells may produce different effects in different tissues, and what the cancer, tissue-repair, regulatory, and long-term safety questions really look like. The bottom line: FOXO4-DRI is a scientifically credible experimental senolytic with compelling preclinical biology—but it has not been proven to reverse aging or provide clinical benefit in humans. Explore the Peptides Explained App: https://app.peptidesexplained.info Peptide Solutions: If you are interested in checking out Compounded or Research Peptide Sources visit Peptide Solutions. https://peptide-solutions.info This episode is educational and is not individualized medical advice. FOXO4-DRI is experimental and is not an FDA-approved medication.

Thymosin alpha 1—also called Tα1 or thymalfasin—is frequently described online as an "immune-boosting peptide." But that phrase oversimplifies a complicated biological system. In this episode of Peptides Explained, John Garrett breaks down how thymosin alpha 1 may influence dendritic cells, Toll-like receptor signaling, T-cell maturation, natural-killer-cell activity, cytokines, and immune regulation. The episode also reviews where it has been studied, including chronic viral hepatitis, vaccine response, oncology-support settings, severe infection, pancreatitis, and sepsis. The evidence is not uniformly positive. Earlier sepsis trials and pooled analyses suggested benefit, but a large multicenter phase 3 trial involving more than 1,100 adults found no reduction in 28-day mortality. That contrast illustrates why biological mechanisms and small clinical studies must be separated from confirmed patient outcomes. The episode also covers: • What thymosin alpha 1 is • Why "immune modulator" is more accurate than "immune booster" • Innate versus adaptive immunity • Human clinical evidence versus cell and animal research • International approval versus U.S. FDA status • FDA concerns involving compounded thymosin alpha 1 • Potential risks, product-quality concerns, and major unknowns • A responsible decision framework for evaluating immune-peptide claims This content is for education and discussion only and is not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any therapy. Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use the link below, I may earn a commission at no additional cost to you. PeptidesExplained.info/OfflinePeptides #ThymosinAlpha1 #Thymalfasin #PeptidesExplained #ImmuneSystem #Immunology #PeptideScience #TCells #Longevity #Peptides #MedicalEducation

After researching peptide science week after week—and using some compounds personally—I'm answering one of the most common questions I receive: Which peptides do I find the most useful and compelling? This is not a universal ranking or a recommendation to use all 11. Tirzepatide, retatrutide, tesamorelin, ipamorelin, BPC-157, TB-500, GHK-Cu, KPV, PT-141, MOTS-c, and SS-31 occupy very different evidence and regulatory categories. Some are FDA-approved prescription drugs. Some have encouraging human data. Others remain experimental and are supported mainly by animal, cell, mechanistic, or anecdotal evidence. In this episode, we examine the problem each peptide is intended to solve, how it works, what the human evidence shows, where the evidence is weak, known risks, regulatory status, and why each compound made my personal list. This episode is for education and discussion only. It is not medical advice. Always involve a qualified healthcare professional before starting, stopping, or changing a therapy. Peptides Explained is an affiliate partner with OfflinePeptides.com. Visit PeptidesExplained.info/OfflinePeptides. For Peptides through a compounding pharmacy or a telehealth option Visit Peptide-Solutions.info and submit a request for more information.